CompletedNCT00360126
A year of lamotrigine after an earlier bipolarity study
About this title
An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder
Read the official source — NCT00360126This study evaluated the safety of lamotrigine for people with bipolarity.
Medication studyAges 18+Australia
Understand this study
What did researchers investigate?
This study evaluated the safety of lamotrigine for people with bipolarity.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
- Listed locations
- Greenwich and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateOctober 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 11
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Australia
- Age range
- Over 18 Years
- Official registry ID
- NCT00360126
- Official title
Show the full official title
An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedGreenwich · Everton Park · New Farm
Questions about this study
What did researchers investigate?
This study evaluated the safety of lamotrigine for people with bipolarity.
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including lamotrigine.
Who was this study for?
This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.
